Last reviewed · How we verify

NCT03407404: KeMiMof

Comparing Clinical Outcomes Between Ketamine-midazolam and Morphine-midazolam for Continous Sedation in ICU Patients.

Terminated Phase 2, PHASE3 Last updated 28 August 2019
What this trial tests

Phase 2, PHASE3 trial testing Ketamine-Midazolam in Critical Illness in 124 participants. Terminated before completion.

Timeline
22 October 2017
Primary endpoint
15 June 2019
30 July 2019

Quick facts

Lead sponsorMakerere University
PhasePhase 2, PHASE3
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment124
Start date22 October 2017
Primary completion15 June 2019
Estimated completion30 July 2019
Sites1 location across Uganda

Drugs / interventions tested

Conditions studied

Sponsor

Makerere University

Who can join

12 and older, any sex, with Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, double-blinded, multicenter randomized control trial. All critically ill patients above 12 years of age requiring continuous sedation for \>24hrs in the ICU will be screened and those meeting selection criteria (and consented) will be enrolled into the study. .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

Other Makerere University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03407404.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing